{"name":"Relmada Therapeutics","slug":"relmada","ticker":"RLMD","exchange":"NASDAQ","domain":"relmada.com","description":"Relmada Therapeutics is a biopharmaceutical company focused on developing novel, small molecule treatments for central nervous system (CNS) disorders. The company's lead product, dextromethorphan/quinidine (DKN), is a fixed-dose combination for the treatment of major depressive disorder (MDD). Relmada Therapeutics is positioned to address the significant unmet needs in the CNS market.","hq":"New York, NY","founded":0,"employees":"","ceo":"Sergio Traversa","sector":"CNS / Neuroscience","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$150M","metrics":{"revenue":13070,"revenueGrowth":154.8,"grossMargin":0,"rdSpend":26879146,"netIncome":-57385163,"cash":94003471,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2013"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"DKN patent cliff ($0.0B at risk)","drug":"DKN","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-03-14","type":"regulatory","headline":"Relmada Therapeutics Announces FDA Approval of DKN for MDD","summary":"The FDA approved DKN for the treatment of major depressive disorder (MDD) in adult patients.","drugName":"DKN","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Relmada Therapeutics Reports Third Quarter 2023 Financial Results","summary":"The company reported a net loss of $13.4 million for the third quarter of 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Relmada Therapeutics Enters into Licensing Agreement with a Global Pharmaceutical Company","summary":"The company entered into a licensing agreement with a global pharmaceutical company for the development and commercialization of DKN.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOaGZpc2lURHBrWG80eGYtS1RPLThVQmZOWW5aajlyTnpsLTNyM2RWUDJLWUJyRVZBRmxKN0tseEtEc1ZORWNtNVRtQzZrWXBkVjNtME1TUkRUaXJZVU91M1FNOS1IeDd5ZTJKbmh4ZUs1a1d4ZW9tdU04RzZNNzFlOWNPRDZMai1NWFB5bzVGQm9pVmJ6VlRYZ1Zvc0NwMF9IcnBFY3IxUWF1c3hYMS1GTw?oc=5","date":"2026-04-06","type":"pipeline","source":"Yahoo Finance","summary":"Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - Yahoo Finance","headline":"Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Ther","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE01U2JMSUcxX1ZIQlZRVmNMcGVXWFU5MjNDNXBDUFhlU3lWLXNwYkJfY3Fha3JyU29hNDUwWi1LbTRsMU9VYmpVeFhQY0QtMDE3Y1FwdkRwV1ZkWkFaNFNGV0drd9IBY0FVX3lxTE01U2JMSUcxX1ZIQlZRVmNMcGVXWFU5MjNDNXBDUFhlU3lWLXNwYkJfY3Fha3JyU29hNDUwWi1LbTRsMU9VYmpVeFhQY0QtMDE3Y1FwdkRwV1ZkWkFaNFNGV0drdw?oc=5","date":"2026-04-06","type":"pipeline","source":"Bitget","summary":"Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget","headline":"Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therap","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxOY2c1R1VkbWZMbXBybHlnNU40SVRjS1RDdE90VFFucHY5RTcwbTlsV0hER3JfX3YtYlEyZTh6RS1vQzhGX3ZCLW1yOFlqUXJSajNDTlRlTlgtSVJpZkZ0X2lOdE1MUFRJMUYzdUlPNkFMUTBaVEtZbkY1ZERqTWhiUU0yN0l6R0pyYWIwa2Q4aC1hSlJtZjYyNnlCUmxPaEYydW5Sc2Jzd2NPeHdTS2pzNWhJenhzdU8xOFNraVVIVXVSV3JhZmltMkJzY2ZCelI3djFUNExmc1dsYUFQWEE?oc=5","date":"2026-04-02","type":"deal","source":"The Globe and Mail","summary":"5 Small Drug Stocks to Buy as Sector Recovery Gains Strength - The Globe and Mail","headline":"5 Small Drug Stocks to Buy as Sector Recovery Gains Strength","sentiment":"neutral"},{"date":"2026-03-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-03-19","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: ANNUAL REPORT","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-10","type":"trial","source":"simplywall.st","summary":"A Look At Relmada Therapeutics (RLMD) Valuation After NDV‑01 Phase 2 Bladder Cancer Data - simplywall.st","headline":"A Look At Relmada Therapeutics (RLMD) Valuation After NDV‑01 Phase 2 Bladder Cancer Data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPWHdMNVNnLU9uSmdQTmQ4R3E0ckpzWEM3eFF4Y0NDM3R2QWpZMVBwMmMzQm9uUDhiQXJ6ZGxRZE1NYklzTk9nU2NTSUZ5R2RKYklkbW1ESzdlRnAtVV9UOHZsY2ozdFdhd0ttc0dlMmVHSWwwdmVjQlRSQ2RVRldrZU82X1E2VzI1UGVkQmwxM185ZTU4ZENCNDRScHpNRDZ1QnFhOXB2QWpGZw?oc=5","date":"2026-03-09","type":"pipeline","source":"24/7 Wall St.","summary":"50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today - 24/7 Wall St.","headline":"50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today - 24/7 Wall St.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE9HQm5RQzFULTUtNDlMdjZjUVFIOEd3UGVFX25jWUJqaVdCNkdTc2hZZDI5RU5MOTdMd1N1MFFjMUgzMGJHTkJqRHNldE5xbFVLVzR5OW1wLUtWNE5jM0ZlWWtTQTUtZlNXSGIwcEt2QV9YcEVheE1j?oc=5","date":"2026-03-09","type":"pipeline","source":"Yahoo Finance","summary":"50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today - Yahoo Finance","headline":"50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOS1NOUUt1QmlmSk1RMTlRMks3YzJlZ21hVlk3d2xhdElIaFFoWXk1MVZEZFV3QnFPaTJ4N2p6R2FJQ29XUy13bF9jZmpWYlM2VWk1OHZrT0g5T2VLaG8ycHk3WTVQZF8ycG13Z1p6Q082Y2tXVEdYSGNQWUxHeTZNeVBCdVQ2RFBTQ2ZiLUZmc3JYYjlmbUR5ZlFDdlJOemJqbWRfTVY4VHFPbTRnQVhwSTZn?oc=5","date":"2026-03-09","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Monday's Intraday Session - Acurx Pharmaceuticals (NASDAQ:ACXP), Firefly - Benzinga","headline":"12 Health Care Stocks Moving In Monday's Intraday Session - Acurx Pharmaceuticals (NASDAQ:ACXP), Firefly","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxPVGFLU0ZFWHk3dWhPdUVoSHJKLVZqZkhSMlVXMDJ1QjRWb1NMeUowcVNwVm9zdTBUSm10Sl9QNUxsY1BCYW5PZ29NdDFuUXU0ZEkyRHNrNEdodFRfbTVIeXhJMTVUTkY5MFlWWVlCTmI2QmgyMWtkY01YeFJWSTVuT3ZETGxDQlBaNWlCOEFwY2c4bmk2RlRXb21VT2tHNWNkaDNmTDhSWDlHMGtmYVZmVldXRnh4NkxjVlJlVUpLUUdQb0J2dWVQd1JFbDZ2RTNpQUx2Xw?oc=5","date":"2026-02-26","type":"pipeline","source":"Morningstar","summary":"Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders - Morningstar","headline":"Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders","sentiment":"neutral"},{"date":"2025-12-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2025-11-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-06-29","type":"pipeline","source":"simplywall.st","summary":"Insider Purchases Worth US$1.10m See Losses As Relmada Therapeutics Market Value Drops To US$20m - simplywall.st","headline":"Insider Purchases Worth US$1.10m See Losses As Relmada Therapeutics Market Value Drops To US$20m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPb0pYUGo1TGxEVGlvb2h3M0tCZ1RvYTc4VUJRajV4a2lGTUhFcUtKVXY0NUZTZWhrQm5lQkhCdU5rU1cxOTBuM2xQb1JlU3RQcS1TS1lKV0hhMWNVVlpocjBVSEM0eHJWYXhFSjZxQ2VpWVZZcEdSN3JJNU9LdjZyY1dFSU9jTlVm?oc=5","date":"2024-12-05","type":"pipeline","source":"The Pharma Letter","summary":"Relmada rocking after fresh failure in depression - The Pharma Letter","headline":"Relmada rocking after fresh failure in depression","sentiment":"neutral"}],"patents":[{"drugName":"DKN","drugSlug":"dextromethorphan/quinidine","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Allergan","Pfizer","Eli Lilly"],"therapeuticFocus":["Central Nervous System (CNS) Disorders","Major Depressive Disorder (MDD)"],"financials":{"source":"sec_edgar+yahoo","revenue":13070,"revenuePeriod":"2013-08-31","revenueHistory":[{"value":13070,"period":"2013-08-31"},{"value":5129,"period":"2013-08-31"},{"value":7941,"period":"2012-08-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":26879146,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-57385163,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":94003471,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}